TULSA, Okla. — The federal government is launching a sweeping crackdown on commercial driver’s license issuers after investigators across the country. Here in Oklahoma, they found undocumented ...
A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and viral ...
Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...
The Transportation Department declared a national emergency Sept. 26 after an audit found widespread failures in how states issue commercial driver licenses to noncitizens. New federal rules require ...
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and Ramsay Hospital Research Foundation ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. In what researchers hope could be a case of 1 + ...
Silvia Maioli receives funding from The Swedish Research Council, Alzheimerfonden, King Gustaf V:s and Queen Victorias Foundation, The private initiative "Innovative ways to fight Alzheimer´s disease ...
Newly arrived Vermonter Ang Dawa Sherpa leads a group up Mount Everest. According to modern historical records, 7,269 recorded individuals have summited Mount Everest, from Edmund Hillary’s ...
Company's shares hit all-time high after trial success Corcept plans to file US marketing application in third quarter Drug relacorilant may get broader label than competitors, analyst says March 31 ...
Coherus BioSciences has launched a randomized Phase 2 study to evaluate the efficacy of casdozokitug (casdozo), an IL-27-antagonistic antibody, combined with toripalimab and bevacizumab for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback